717-44-2

Upstream product

• 104-15-4 toluene-4-sulfonic acid 
• 98-59-9 p-toluenesulfonyl chloride 
• 2767-77-3 toluene-2,4-disulfonyl dichloride 

Downstream Products

• 1345021-03-5 6-aminosulfonyl-3-(4-ethylphenyl)-1,2-benzoisothiazole 1,1-dioxide 
• 65952-16-1 2-benzyl-3-oxo-2,3-dihydro-1,2-benzothiazole-6-sulfonamide 1,1-dioxide 
• 1374988-40-5 3-oxo-2-(2-phenylethyl)-2,3-dihydro-1,2-benzothiazole-6-sulfonamide 1,1-dioxide 
• 6125-28-6 6-Sulfamoyl-2-methyl-saccharin 

Relevant academic research and scientific papers

Glyoxalase 1 and 2 enzyme inhibitory activity of 6-sulfamoylsaccharin and sulfocoumarin derivates

The glyoxalase enzymes represent a cellular defence system against the accumulation of cytotoxic α-oxoaldehydes leading to apoptosis. The potential of glyoxalase inhibitors to act as novel anti-cancer agents for drugresistant tumours that over-express gly

Synthesis of 6-sulfamoylsaccharin and study of its reactivity in alkylation reactions

An improved method for the preparation of 6-sulfamoylsaccharin (3-oxo-2,3-dihydro-1,2-benzothiazole-6-sulfonamide 1,1-dioxide) has been developed and studies of its possible direct alkylation have been carried out. It was shown that alkylation occursregio

Design, synthesis and biological evaluation of benzo[1.3.2]dithiazolium ylide 1,1-dioxide derivatives as potential dual cyclooxygenase-2/5-lipoxygenase inhibitors

3-(4-Bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide (5) was discovered as a new prototype for dual inhibitors of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). Thus, the structure-activity relationships of benzo[1.3.2]dithiazolium ylide 1,1-dioxide skeleton were carried out. The 6-NO2 group played an essential role in the inhibitory activity. In addition, moderate-sized lipophilic substituents at the para-position of the 3-aryl moiety were required for dual COX-2/5-LOX inhibitory activity. Among the identified potent dual inhibitors, 3-(4-tbutylphenyl) derivative 30c (IC50 values of 0.27 μM and 0.30 μM against COX-2 and 5-LOX, respectively) and 3-(4-biphenyl) derivative 30f (IC50 values of 0.50 μMand 0.15 μMagainst COX-2 and 5-LOX, respectively) were the most potent dual COX-2/ 5-LOX inhibitors. Intraperitoneal administration of 30c at 100 mg/kg demonstrated potent acute antiinflammatory activity. As a result, benzo[1.3.2]dithiazolium ylide 1,1-dioxide represented a novel scaffold for the exploitation in developing dual COX-2/5-LOX inhibitors.